Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells

Urologia Internationalis

Volumn 86, Issue 3, 2011, Pages 346-354

  Wu, Deyao ^a   Tao, Jun ^a   Xu, Bin ^a   Qing, Weijie ^a   Li, Pengchao ^a   Lu, Qiang ^a   Zhang, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Doxorubicin chemotherapy; LY294002; PI3K inhibitor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; INHIBITORY CONCENTRATION 50; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TETRAZOLIUM SALTS; THIAZOLES; URINARY BLADDER NEOPLASMS;

EID: 79955118584     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322986     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Sharma S, Ksheersagar P, Sharma P: Diagnosis and treatment of bladder cancer. Am Fam Physician 2009; 80: 717-723.
3. Kroft SH, Oyasu R: Urinary bladder cancer: mechanisms of development and progression. Lab Invest 1994; 71: 158-174. (Pubitemid 24278167)
4. Herr HW: High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin Urol Oncol 1997; 15: 142-146. (Pubitemid 27360582)
5. Dovedi SJ, Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 2009; 28: 355-367.
6. Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, Roberts JT, Uscinska BM, Griffiths GO, Parmar MK: A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998; 78: 1067-1075. (Pubitemid 28463984)
7. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T, Takahashi K, Tomita Y: Prognostic impact of FAS/CD95/ APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005; 93: 544-551. (Pubitemid 43079997)
8. Koyasu S: The role of PI3K in immune cells. Nat Immunol 2003; 4: 313-319.
9. Gelman AE, LaRosa DF, Zhang J, Walsh PT, Choi Y, Sunyer JO, Turka LA: The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 2006; 25: 783-793. (Pubitemid 46107281)
10. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63: 2742-2746. (Pubitemid 36667143)
11. Neve RM, Holbro T, Hynes NE: Distinct roles for phosphoinositide 3-kinase, mitogen- activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002; 21: 4567-4576. (Pubitemid 34785733)
12. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA: The phosphatidylinositol 3′- kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-7429. (Pubitemid 32995029)
13. Xing CG, Zhu BS, Fan XQ, Liu HH, Hou X, Zhao K, Qin ZH: Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol 2009; 15: 5044-5052.
14. Lee S, Choi EJ, Jin C, Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005; 97: 26-34. (Pubitemid 40403670)
15. Kim S, Lee TJ, Park JW, Kwon TK: Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J Cell Biochem 2008; 105: 971-979.
16. Liu P, Xu B, Li J, Lu H: LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway. Biochem Biophys Res Commun 2008; 377: 187-190.
17. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S: Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and druginduced apoptosis. Cancer Res 2008; 68: 6271-6280.
18. Su JC, Lin KL, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR: Naphtho[1,2-b]furan- 4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. Life Sci 2010; 86: 207-213.
19. Thamilselvan V, Craig DH, Basson MD: FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 2007; 21: 1730-1741. (Pubitemid 46855619)
20. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
21. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274. (Pubitemid 46962095)
22. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39. (Pubitemid 28458022)
23. Martin-Berenjeno I, Vanhaesebroeck B: PI3K regulatory subunits lose control in cancer. Cancer Cell 2009; 16: 449-450.
24. Saal LH, Johansson P, Holm K, Gruvberger- Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569. (Pubitemid 47185946)
25. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide- 3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324-2330. (Pubitemid 30307208)
26. Schenk-Braat EA, Bangma CH: Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 2005; 54: 414-423. (Pubitemid 40543681)
27. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL: Intravesical treatments of bladder cancer: review. Pharm Res 2008; 25: 1500-1510.
28. Richie JP: Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992; 19: 521-527.
29. Speers AG, Lwaleed BA, Featherstone JM, Sallis BJ, Cooper AJ: Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J Clin Pathol 2006; 59: 912-915. (Pubitemid 44422842)
30. Nakagawa M, Emoto A, Nasu N, Hanada T, Kuwano M, Cole SP, Nomura Y: Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997; 157: 1260-1264, discussion 1264-1265.
31. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T, Suzuki Y: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008; 27: 76.
32. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4: 977-986. (Pubitemid 40909080)
33. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
34. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G: The phosphatidylinositol- 3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-1357.
35. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
36. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
37. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, Dent P: OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008; 73: 1168-1184. (Pubitemid 351439199)
38. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform- selective inhibition. Biochem J 2008; 415: 97-110.
39. Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du- Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ: Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 2008; 7: 2621-2632.
40. Morgensztern D, McLeod HL: PI3K/Akt/ mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16: 797-803. (Pubitemid 41215743)
41. Yau CY, Wheeler JJ, Sutton KL, Hedley DW: Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65: 1497-1504. (Pubitemid 40270179)
42. Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
43. Ng SS, Tsao MS, Nicklee T, Hedley DW: Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-3275. (Pubitemid 32963853)
44. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000; 90: 39-44. (Pubitemid 30317175)
45. Kong D, Yamori T: Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 2008; 99: 1734-1740.
46. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, Martelli AM: Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/ AKT pathway. Br J Haematol 2005; 129: 677-686. (Pubitemid 40825830)